Improving lung cancer treatment through biomarker discovery and targeted therapies
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center
['FUNDING_OTHER'] · EMORY UNIVERSITY · NIH-10796803
This study is working to improve treatment for lung cancer patients by finding new markers that can help doctors choose the best therapies for each person, so they can get more personalized and effective care.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EMORY UNIVERSITY (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-10796803 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing treatment outcomes for lung cancer patients by developing novel biomarkers that can guide targeted therapies and immunotherapy. The team at Emory University collaborates with various institutions to share specimens and conduct pilot projects that are directly relevant to clinical trials. By utilizing genomic, epigenomic, and proteomic approaches, the research aims to identify effective combination treatments and overcome resistance to existing therapies. Patients may benefit from personalized treatment plans based on their unique biomarker profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with lung cancer who may benefit from targeted therapies and biomarker-driven treatments.
Not a fit: Patients with lung cancer who are not eligible for targeted therapies or those with advanced disease not amenable to further treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for lung cancer patients.
How similar studies have performed: Previous research has shown success in using biomarker-driven approaches to improve lung cancer treatment outcomes, indicating that this approach is both relevant and promising.
Where this research is happening
ATLANTA, UNITED STATES
- EMORY UNIVERSITY — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LEAL, TICIANA — EMORY UNIVERSITY
- Study coordinator: LEAL, TICIANA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.